2 CG Oncology insiders buy within 14 days
Two CG Oncology
- $2,665,586.25[1]
Two CG Oncology (CGON) insiders bought stock within 14 days, Form 4 filings show: 2 purchases totaling $2,665,586.25 on Nov 18. The largest was Arthur Kuan, chief executive officer, at $2,366,425.24.[1]
| Insider | Role | Trade date | Shares | Value | Reporting delay |
|---|---|---|---|---|---|
| Arthur Kuan | chief executive officer | 2026-11-18 | 30,000 | $2,366,425.24 | the same day |
| Isabel Kalofonos | chief commercial officer | 2026-11-18 | 3,751 | $299,161.01 | the same day |
How unusual is the group?
0 further insiders filed a purchase at CGON in the 14 days before the earliest trade in this group.[2]
CGON insider trading activity
In open-market trades dated in the last 90 days, 2 insiders bought $2.7M and 1 insider sold $165K, all of it under preset trading plans, per Form 4 filings.
- Arthur Kuan (Chief Executive Officer) bought 30,000 shares for $2.4M, last filed Nov 18.
- Isabel Kalofonos (Chief Commercial Officer) bought 3,751 shares for $299K, last filed Nov 18.
- Leonard E. Post (Director) sold 2,000 shares for $165K under a preset plan, last filed Nov 17.
Get CGON alerts
Set a CGON price alert, or get one when a fund, insider or politician you follow trades.
CGON 13F fund activity
In 13F filings for the quarter ended Jun 30, 2026, 2 funds we track made a large change in CGON: none opened or grew a position by half or more, and 2 cut one by half or more, 2 of them selling out completely.
- Farallon Capital Management, L.l.c. sold all 674,000 shares, leaving no position.
- Point72 Asset Management, L.P. sold all 399,392 shares, leaving no position.
Sources
Keep reading
Built by fixed rules from the filing as filed, with no AI writing. A filing does not show why anyone traded. Report a correction.